Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Travere Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Travere Therapeutics, Inc.’s stock price such as:

• Travere Therapeutics, Inc.’s current stock price and volume
• Why Travere Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TVTX from analysts
• TVTX’s stock price momentum as measured by its relative strength

About Travere Therapeutics, Inc. (TVTX)

Before we jump into Travere Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Want to learn more about Travere Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Travere Therapeutics, Inc..

Travere Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Travere Therapeutics, Inc.’s stock price was $55.890.

Travere Therapeutics, Inc. is down 2.43% from its previous closing price of $57.280.

During the last market session, Travere Therapeutics, Inc.’s stock traded between $55.304 and $57.550. Currently, there are approximately 91.87 million shares outstanding for Travere Therapeutics, Inc..

Travere Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Travere Therapeutics, Inc. Stock Price History

Travere Therapeutics, Inc.’s (TVTX) price is currently down 1.62% so far this month.

During the month of July, Travere Therapeutics, Inc.’s stock price has reached a high of $60.000 and a low of $53.000.

Over the last year, Travere Therapeutics, Inc. has hit prices as high as $60.100 and as low as $15.030. Year to date, Travere Therapeutics, Inc.’s stock is up 46.27%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Travere Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Travere Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Travere Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Travere Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Travere Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Travere Therapeutics, Inc. (TVTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Travere Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Travere Therapeutics, Inc. has a weighted four-quarter relative price strength of 32.43%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Travere Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Travere Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Travere Therapeutics, Inc.’s stock price is $55.890, which is down 2.43% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Travere Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.